Compare Novartis AG (NVS) vs Zillow Group Inc Class C (Z) Price & Performance

Novartis (NVS) trades at $143.22, down 0.04% on the day, near the analyst consensus price target of $146. The stock shows mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company reported strong 2025 revenue of $56.67B and net income of $13.98B, with a robust net margin of 24.67%. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though this follows clinical setbacks in other drug programs.

The outlook is cautiously optimistic. The Abogen deal expands the pipeline in autoimmune diseases, a growth area, and analyst consensus leans Hold with a slight upside to the price target. Key risks include integration challenges from recent acquisitions, pipeline volatility after trial failures, and investor scrutiny over M&A strategy. Earnings momentum is mixed, with a recent beat in Q2 but a miss in Q1, requiring consistent execution to justify current valuations.

Zillow Group (Z) trades at $28.84, up 5.72% in the last session, showing strong momentum despite mixed technical signals. The company has demonstrated improving fundamentals with revenue growing from $2.2B in 2024 to $2.6B in 2025, turning a net loss of $112M into a $23M profit. Recent earnings show beats in Q1 and Q2 2026, though Q4 2025 missed expectations. Analyst sentiment is divided with a $60.33 consensus price target representing significant upside potential from current levels.

Zillow presents a compelling growth story with improving profitability and strong analyst targets, but faces headwinds from housing market volatility and rising mortgage rates. The stock's high P/E ratio of 126.83 reflects growth expectations, while technical indicators show conflicting signals with bullish overall momentum but bearish moving averages. The resolution of the FTC lawsuit removes regulatory overhang, but competition with Compass and market sensitivity to interest rates remain key risks.